Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.
Charles Ryan, MD, associate clinical professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma (RCC).
In a study presented at the 2014 Genitourinary Cancers Symposium, researchers looked to describe the context in which physicians would prescribe a given therapeutic in either disease. Ryan provides the example that in RCC, researchers found a strong preference for community oncologists to prescribe mTOR-targeted therapies in the second-line setting, which is supported by literature and regulatory approvals. There may be different contexts in which prescribing patterns evolve.
Ryan says he found that data to be interesting and believes that this information is worth having.